TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31442618
Drug: Lifestyle and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle and occupational exposures (including age, BMI, cigarette smoking, regular exercise, daily vehicle vibration)
Study: 22420645
Drug: Combined spinal-epidural
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spinal-epidural (CSE) with intrathecal bupivacaine 2.5 mg and fentanyl 5 μg
Study: 22420645
Drug: Epidural with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural with bupivacaine 20 mg and fentanyl 40 μg
Study: 17895472
Drug: High-dose sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sorafenib
Study: 11384572
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (100 mg)
Study: 9880383
Drug: Clomethiazole (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomethiazole (75 mg/kg)
Study: 28817997
Drug: Cladribine 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine 3.5 mg/kg
Study: 25157992
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and surgery (case group)
Study: 22257503
Drug: Constraint-induced movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced movement therapy
Study: 17487652
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg 17beta‐estradiol (E2) + 0.25 mg norethisterone acetate (NETA)
Study: 17487652
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg E2 + 0.1 mg NETA
Study: 9635933
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 microg twice daily for 3 weeks)
Study: 9635933
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 microg twice daily for 3 weeks)
Study: 3275894
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg every six hours)
Study: 849673
Drug: Thioridazine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (high dose)
Study: 849673
Drug: Thioridazine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (low dose)
Study: 849673
Drug: Thioridazine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (high and low doses)
Study: 22208805
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone ER 40 mg with 240 mL of ethanol 20%
Study: 22208805
Drug: Oxymorphone CRF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone CRF 40 mg with 240 mL of ethanol 40%
Study: 10899655
Drug: Sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential methotrexate and 5-fluorouracil (MF)
Study: 8523236
Drug: D-[U-13C]glucose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-[U-13C]glucose (100 mg/kg)
Study: 8523236
Drug: Intravenous 10%
Normalized name: fat emulsion, intravenous 10% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 10% dextrose (D10W)
Study: 17261652
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg clopidogrel daily maintenance dose
Study: 7874944
Drug: Limited pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited pulmonary rehabilitation program focused on coping strategies for shortness of breath (6-week treatment)
Study: 2571815
Drug: Psychosocial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychosocial intervention (weekly supportive group therapy with self-hypnosis for pain)
Study: 930916
Drug: Total duration
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total duration of oral contraceptive use
Study: 25041550
Drug: Non-surgical mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical mechanical periodontal treatment (test group, n = 32)
Study: 20180933
Drug: Crushed tablets
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed tablets with concomitant meal
Study: 20180933
Drug: Dispersible tablets
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablets with concomitant meal
Study: 20180933
Drug: Crushed tablets
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed tablets with milk
Study: 20180933
Drug: Dispersible tablets
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablets with milk
Study: 18288237
Drug: Lactobacillus crispatus
Normalized name: LACTOBACILLUS CRISPATUS
DrugBank: Lactobacillus crispatus strain CTV-05 (DB19093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus crispatus CTV‐05 vaginal suppository
Study: 29943384
Drug: Placebo vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppository
Study: 12419098
Drug: Pemirolast potassium
Normalized name: Pemirolast Potassium
DrugBank: Pemirolast (DB00885)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pemirolast potassium 0.1% ophthalmic solution
Study: 9860152
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg alone
Study: 9860152
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg after 2 weeks of carbamazepine 200 mg BID
Study: 897864
Drug: L-leucine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-leucine therapy
Study: 897864
Drug: Single loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single loading doses of L-kynurenine
Study: 31079282
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AIs) - Exemestane and Letrozole
Study: 27472858
Drug: Hot-pack +
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot-pack + laser therapy 1 (850 nm Ga-Al-As laser)
Study: 27472858
Drug: Hot-pack +
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot-pack + laser therapy 2 (650 nm He-Ne, 785 ve 980 nm Ga-Al-As combined plaque laser)
Study: 18276744
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg/day for 2 years followed by 10 mg/day for 1 year
Study: 17013567
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 mcg/day
Study: 17013567
Drug: Teriparatide 40
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide 40 mcg/day
Study: 14624219
Drug: Misoprostol as
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol as a single agent
Study: 11192134
Drug: Clarithromycin extended-release
Normalized name: Clarithromycin Extended-Release Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin extended-release (once-daily for 14 days)
Study: 11192134
Drug: Clarithromycin immediate-release
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin immediate-release (twice-daily for 14 days)
Study: 11192133
Drug: Clarithromycin immediate-release
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin immediate-release
Study: 9201523
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii 500 mg four times a day
Study: 9201523
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii 500 mg four times a day (after adjustment for risk factors)
Study: 7835781
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no hormonal treatment)
Study: 2972171
Drug: Danazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (200 mg, 3 times daily)
Study: 2972171
Drug: High-dose Medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Medroxyprogesterone Acetate (MPA) (100 mg daily)
Study: 12799617
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (risperidone, clozapine, olanzapine, quetiapine)
Study: 10513172
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (LR group, n = 10)
Study: 10513172
Drug: Acetated Ringer's
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer's solution (AR group, n = 10)
Study: 27513296
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy (SET)
Study: 23826157
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment for 12 weeks
Study: 17361345
Drug: Albuterol (sustained-release,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (sustained-release, 8 mg bid)
Study: 9238064
Drug: Lupron alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupron alone (gonadotropin-releasing hormone agonist)
Study: 8116741
Drug: 5-fluorouracil (five
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (five injections of 5 mg during two weeks after surgery)
Study: 28068186
Drug: PDT+chitosan 3 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT+chitosan 3 mg/mL
Study: 24351694
Drug: Midazolam (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (doses of at least 0.3 mg/kg)
Study: 24351694
Drug: Midazolam (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (any dose)
Study: 12707092
Drug: Daily sunscreen
Normalized name: ZINC OXIDE 220 mg in 1 mL TOPICAL CREAM [SPF 30 Daily Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sunscreen application (high-protection sunscreen applied every morning)
Study: 12707092
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene supplementation (30 mg/day)
Study: 1568574
Drug: Immediate start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate start of steroid tapering (group A; n = 46)
Study: 1568574
Drug: Continued prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued prednisolone treatment for 5 more weeks before tapering (group B; n = 50)
Study: 6232035
Drug: Etodolac, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac, 1200 mg/day
Study: 6232035
Drug: Aspirin, 2600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 2600 mg/day
Study: 29408818
Drug: Conventional restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional restorative treatment (CRT)
Study: 17378909
Drug: Somatostatin 250
Normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin 250 microg/h continuous IV infusion for 48 h after a bolus of 250 microg
Study: 17378909
Drug: Somatostatin 250
Normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin 250 microg/h continuous IV infusion for 48 h
Study: 15972934
Drug: Low toenail
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low toenail chromium concentration (average 1.10 mug/g in cases)
Study: 15972934
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (average toenail chromium concentration 1.30 mug/g)
Study: 30300054
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow restriction (BFR) therapy combined with low-resistance muscular training for 15 weeks
Study: 30300054
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow restriction (BFR) therapy combined with low-resistance muscular training for 13 days
Study: 22832470
Drug: Error-augmentation training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Error-augmentation training
Study: 17031007
Drug: Chitosan (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan (six 500 mg capsules per day)
Study: 13678871
Drug: Candesartan (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (32 mg once daily)
Study: 11051260
Drug: Docetaxel 70
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 70 mg/m2 followed by Doxorubicin 50 mg/m2
Study: 11051260
Drug: Doxorubicin 50
Normalized name: DOXOrubicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 followed by Docetaxel 60 mg/m2
Study: 8266157
Drug: Lignocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine spray
Study: 9176438
Drug: Lignocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine spray and Placebo
Study: 3568540
Drug: Ketorolac 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 90 mg
Study: 3568540
Drug: Morphine 12
Normalized name: morphine 120 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 12 mg
Study: 9283163
Drug: Morphine 6
Normalized name: apomorphine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 6 mg
Study: 19531276
Drug: Self-management plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management plus treatment as usual (TAU) (n=31)
Study: 19531276
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) control condition (n=33)
Study: 15824372
Drug: Indinavir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir treatment
Study: 10402766
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin 70 mg/m2 on day 1, fluorouracil 700 mg/m2 and leucovorin 20 mg/m2 on days 1 to 5)
Study: 10402766
Drug: Surgery (immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery (immediate surgery without chemotherapy)
Study: 28050801
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg (D4)
Study: 11093989
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg (D10)
Study: 21255753
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream during tDCS stimulation
Study: 18974529
Drug: Inami L‐5110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inami L‐5110 (GATI)
Study: 17054744
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of mefloquine and artesunate
Study: 17054744
Drug: New fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: New fixed combination of mefloquine and artesunate
Study: 15189956
Drug: β2-agonist (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: β2-agonist (single dose)
Study: 3777548
Drug: Moderate normovolaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate normovolaemic haemodilution induced with a colloid solution (Plasmion)
Study: 31461801
Drug: 5 μg dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg dexmedetomidine
Study: 31461801
Drug: 50 mg MgSO4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg MgSO4
Study: 27316483
Drug: ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 5 mg twice daily for 6 weeks
Study: 20353120
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection at Neiguan (PC 6) with 2.5 mg Droperidol (1 mL)
Study: 20353120
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection with 1 mL Droperidol
Study: 18718815
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone (goserelin and anastrozole or goserelin and tamoxifen)
Study: 18718815
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy with zoledronic acid (goserelin, anastrozole, and zoledronic acid or goserelin, tamoxifen, and zoledronic acid)
Study: 18718815
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone (without zoledronic acid)
Study: 12860219
Drug: berberine 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: berberine 1.2 to 2.0 g/day
Study: 11028252
Drug: Intravenous RGD891
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous RGD891
Study: 3899397
Drug: Mefloquine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (1000 mg single oral dose)
Study: 6360400
Drug: Sulfadoxine-pyrimethamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (2 tablets, each containing 500 mg of sulfadoxine plus 25 mg of pyrimethamine)
Study: 26398741
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of MenACWY-CRM (ACWY2)
Study: 26398741
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of placebo followed by 1 dose of MenACWY-CRM (ACWY1)
Study: 24876616
Drug: Standard pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pump therapy with delayed CGM initiation
Study: 18971247
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch application
Study: 3324800
Drug: Saline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline treatment
Study: 30558984
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with oral ciprofloxacin (2 doses prior to urinary catheter removal)
Study: 30558984
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotics prior to urinary catheter removal)
Study: 30558984
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with oral ciprofloxacin
Study: 25183287
Drug: Dexmedetomidine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.8 μg kg(‐1) h(‐1))
Study: 22429618
Drug: Topical mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mydriatics (TM)
Study: 21425144
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with loop electrical excision procedure (LEEP)
Study: 17310835
Drug: Adjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormone therapy by antiandrogens
Study: 17310835
Drug: Antineoplastic chemotherapeutic
Normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antineoplastic chemotherapeutic agents such as estramustine and taxanes
Study: 17310835
Drug: Neoadjuvant therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapies including systemic therapy before or after local treatment
Study: 9672930
Drug: Intramuscular tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular tenoxicam 0.75 mg.kg‐1
Study: 9672930
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine sulphate 0.2 mg.kg‐1
Study: 31807987
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (IMT) at 40% of maximal inspiratory pressure (MIP), 5 sessions weekly, 10-20 min/session
Study: 30686636
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg for 28 days
Study: 30686636
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of atorvastatin vs placebo
Study: 26498129
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (∼14 g day(‐1) NaCl)
Study: 26498129
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg, non-selective COX-1 and COX-2 inhibitor)
Study: 26498129
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg, selective COX-2 inhibitor)
Study: 15553106
Drug: emedastine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: emedastine 4 mg o.d.
Study: 31443735
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (rehabilitation treatment)
Study: 21324184
Drug: Weekly docetaxel-based
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel-based chemotherapy
Study: 21324184
Drug: 3-weekly docetaxel-based
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel-based chemotherapy
Study: 18304128
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 7 micro/kg
Study: 17699253
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (prednisolone, azathioprine, warfarin, and dipyridamole)
Study: 17699253
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment and Prednisolone alone
Study: 12714472
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (spinal mobilisation)